Molecular requirements for the combined effects of TRAIL and ionising radiation

Radiotherapy and Oncology

Volumn 68, Issue 2, 2003, Pages 189-198

  Marini, Patrizia ^a   Jendrossek, Verena ^a   Durand, Elise ^a   Gruber, Charlotte ^a   Budach, Wilfried ^a   Belka, Claus ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE   (Germany)

Author keywords

APAF, apoptosis protease activating factor; Apoptosis; Combined effects; DISC, death inducing signalling complex; FADD, Fas associated death domain protein; FADD DN, transdominant negative acting fas associated death domain protein; Radiation; TRAIL

Indexed keywords

CASPASE 10; CASPASE 3; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RECEPTOR SUBTYPE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; CASP8 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CASPASE; CASPASE 9; FADD PROTEIN, HUMAN; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TNFRSF10A PROTEIN, HUMAN; TNFRSF10B PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER RADIOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IONIZING RADIATION; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL SURVIVAL; DRUG EFFECT; METABOLISM; RADIATION EXPOSURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CASPASE 8; CASPASE 9; CASPASES; CELL SURVIVAL; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; JURKAT CELLS; MEMBRANE GLYCOPROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0345933237     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(03)00186-5     Document Type: Article

References (57)

1. Ashkenazi A., Pai R.C., Fong S., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:1999;155-162.
2. Belka C., Heinrich V., Marini P., et al. Ionizing radiation and the activation of caspase-8 in highly apoptosis-sensitive lymphoma cells. Int J Radiat Biol. 75:1999;1257-1264.
3. Belka C., Knippers P., Rudner J., Faltin H., Bamberg M., Budach W. MEK1 and Erk1/2 kinases as targets for the modulation of radiation responses. Anticancer Res. 20:2000;3243-3249.
4. Belka C., Rudner J., Wesselborg S., et al. Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis. Oncogene. 19:2000;1181-1190.
5. Belka C., Schmid B., Marini P., et al. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene. 20:2001;2190-2196.
6. Bodmer J.L., Holler N., Reynard S., et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol. 2:2000;241-243.
7. Brockhaus M., Schoenfeld H.J., Schlaeger E.J., Hunziker W., Lesslauer W., Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA. 87:1990;3127-3131.
8. Cecconi F. Apaf1 and the apoptotic machinery. Cell Death Differ. 6:1999;1087-1098.
9. Chinnaiyan A.M., O'Rourke K., Tewari M., Dixit V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 81:1995;505-512.
10. Chinnaiyan A.M., Tepper C.G., Seldin M.F., O'Rourke K., Kischkel F.C., Hellbardt S., et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem. 271:1996;4961-4965.
11. Chinnaiyan A.M., Prasad U., Shankar S., et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA. 97:2000;1754-1759.
12. Smyth M.J. Increased suspectibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol. 168:2002;1356-1361.
13. Cuello M., Ettenberg S.A., Nau M.M., Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol. 81:2001;380-390.
14. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7:1997;813-820.
15. Ellis R.E., Yuan J.Y., Horvitz H.R. Mechanisms and functions of cell death. Annu Rev Cell Biol. 7:1991;663-698.
16. Ferrari D., Stepczynska A., Los M., Wesselborg S., Schulze-Osthoff K. Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis. J Exp Med. 188:1998;979-984.
17. Gong B., Almasan A. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res. 60:2000;5754-5760.
18. Hengartner M.O., Horvitz H.R. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell. 76:1994;665-676.
19. Hu W.H., Johnson H., Shu H.B. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem. 274:1999;30603-30610.
20. Juo P., Kuo C.J., Yuan J., Blenis J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol. 8:1998;1001-1008.
21. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59:1999;734-741.
22. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 12:2000;611-620.
23. Kischkel F.C., Lawrence D.A., Tinel A., et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem. 276:2001;46639-46646.
24. Kuida K., Haydar T.F., Kuan C.Y., et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell. 94:1998;325-337.
25. Lawrence D., Shahrokh Z., Marsters S., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 7:2001;383-385.
26. Leverkus M., Walczak H., McLellan A., et al. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. Blood. 96:2000;2628-2631.
27. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:1998;491-501.
28. Locksley R.M., Killeen N., Lenardo M.J., The T.N.F. and TNF receptor superfamilies: integrating mammalian biology. Cell. 104:2001;487-501.
29. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
30. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94:1998;481-490.
31. MacFarlane M., Ahmad M., Srinivasula S.M., Fernandes-Alnemri T., Cohen G.M., Alnemri E.S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem. 272:1997;25417-25420.
32. Marsters S.A., Sheridan J.P., Pitti R.M., et al. novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 7:1997;1003-1006.
33. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
34. Mundt B., Kuhnel F., Zender L., et al. Involvement of TRAIL and its receptors in viral hepatitis. Faseb J. 17:2003;94-96.
35. Muzio M., Chinnaiyan A.M., Kischkel F.C., et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death - inducing signaling complex. Cell. 85:1996;817-827.
36. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
37. Pan G., O'Rourke K., Chinnaiyan A.M., et al. The receptor for the cytotoxic ligand TRAIL. Science. 276:1997;111-113.
38. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277:1997;815-818.
39. Peter M.E. The TRAIL Discussion: It is FADD and caspase-8! Cell Death Differ. 7:2000;759-760.
40. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271:1996;12687-12690.
41. Rosse T., Olivier R., Monney L., et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature. 391:1998;496-499.
42. Rudner J., Lepple-Wienhues A., Budach W., et al. Wild-type, mitochondrial and ER-restricted Bcl-2 inhibit DNA damage-induced apoptosis but do not affect death receptor-induced apoptosis. J Cell Sci. 114:2001;4161-4172.
43. Rudner J., Belka C., Marini P., et al. Radiation sensitivity and apoptosis in human lymphoma cells. Int J Radiat Biol. 77:2001;1-11.
44. Ruiter G.A., Zerp S.F., Bartelink H., van Blitterswijk W.J., Verheij M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res. 59:1999;2457-2463.
45. Scaffidi C., Fulda S., Srinivasan A., et al. Two CD95 (APO-1/Fas) signaling pathways. Embo J. 17:1998;1675-1687.
46. Sheikh M.S., Burns T.F., Huang Y., et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 58:1998;1593-1598.
47. Sheridan J.P., Marsters S.A., Pitti R.M., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:1997;818-821.
48. Schneider P., Thome M., Burns K., et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity. 7:1997;831-836.
49. Soengas M.S., Alarcon R.M., Yoshida H., et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 284:1999;156-159.
50. Stroh C., Schulze-Osthoff K. Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Differ. 5:1998;997-1000.
51. Takeda K., Smyth M.J., Cretney E., et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med. 195:2002;161-169.
52. Tenzer A., Zingg D., Rocha S., et al. The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res. 61:2001;8203-8210.
53. Walczak H., Degli-Esposti M.A., Johnson R.S. et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:1997;5386-5397.
54. Walczak H., Miller R.E., Ariail K., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5:1999;157-163.
55. Wang J., Chun H.J., Wong W., Spencer D.M., Lenardo M.J. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA. 98:2001;13884-13888.
56. Yeh W.C., Pompa J.L., McCurrach M.E., et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 279:1998;1954-1958.
57. Yuan J., Shaham S., Ledoux S., Ellis H.M., Horvitz H.R., The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell. 75:1993;641-652.